CD274 and neoplasm: Beyond antigen presentation, exosomes engineered to inhibit immune checkpoints or deliver checkpoint blockade antibodies (e.g., anti‐PD‐1 or anti‐PD‐L1) can counteract immunosuppressive signals in the tumor microenvironment, enhancing anti‐tumor immunity.[112] Through these versatile functions, exosomes present a novel and promising strategy to overcome the current challenges of immunotherapy, offering a more effective and personalized approach to cancer treatment.